Cytokinetics (CYTK)
NASDAQ:CYTK
Want to see CYTK full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.66Last Year’s EPS
-1.12Same Quarter Last Year
Strong Buy
Based on 19 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed multiple major positive developments: first commercial launch with encouraging early uptake and revenue, EU approval and imminent German launch, positive pivotal Acacia HCM topline results that could expand aficamtin to nonobstructive HCM, and continued pipeline progress and regulatory filings. Offsetting these positives are meaningful launch and operating costs (SG&A up sharply), continued cash burn, incomplete payer access early in launch, and notable safety observations in Acacia HCM (higher incidence of LVEF decline and a small number of serious heart failure events) that will require regulatory and prescriber scrutiny. On balance, the transformative commercial and clinical milestones materially outweigh the near-term financial and safety challenges described on the call.Company Guidance
First Commercial Product Launch and Initial Revenue
Launched MYCorzo in the U.S. (available to patients Jan 27). Recorded $4.8 million in net product revenue in Q1 (approx. nine weeks of commercial sales); over 70% of dispensed patients on a paid prescription and average conversion to paid in <2 weeks.
Strong Early Commercial Adoption Metrics
By end of Q1 ~275 unique HCPs prescribed MYCorzo (50%+ from high-volume prescribers); through April >425 HCPs prescribing. Average prescriptions per HCP: 2.4 overall / 2.6 for high-volume prescribers. Internal estimate of new-to-brand Q1 exit share >30%. Over 1,400 HCPs REMS-certified and >2,100 enrolled in the patient community; ~680 patients prescribed by end of Q1 rising to ~1,100 through April.
European Regulatory Progress and Commercial Expansion
European Commission approved MYCorzo in February; German commercial launch planned in Q2 2026. Six HTA dossiers submitted with five more expected this quarter; MAA submitted to Swissmedic; Canadian decision expected in H2 2026.
Positive Pivotal Acacia HCM Results (aficamtin in nHCM)
Acacia HCM met both dual primary endpoints: KCCQ improvement LS mean difference 3.0 points (11.4 vs 8.4; p=0.021) and peak VO2 LS mean difference 0.67 mL/kg/min (0.64 increase vs -0.03; p=0.003). Statistically significant secondary endpoint improvements (NYHA class, composite ventilatory efficiency/peak VO2, NT-proBNP). No new safety signals identified overall. Company plans regulatory discussions and potential sNDA submission.
Regulatory and Label Expansion Pathway
sNDA for MAPLE HCM accepted for filing by FDA with PDUFA date 11/14/2026; MAA submitted for oHCM in Switzerland; marketing application under review in Canada; Sanofi partner progressing potential approvals in Hong Kong and Taiwan.
Collaboration and Milestone Revenue Recognition
Recorded $11.9 million milestone under the Bayer license agreement tied to first U.S. commercial sale. Collaboration revenue $2.6M in Q1 vs $1.6M in Q1 2025 (+62.5%).
Pipeline and Ongoing Trials Progress
Ongoing global programs: CAMELLIA-HCM (Japan), CEDAR-HCM (pediatric; adolescent cohort enrollment expected complete by end of 2026), COMET-HS enrollment progressing (omicamtiv program), and AMBER-HFpEF cohort 1 enrollment expanded (expect completion in 2H 2026). Afibcamtin received orphan designation in Japan for nHCM and pediatric oHCM.
Maintained Full-Year Financial Guidance and Large Cash Position
Maintained full-year 2026 GAAP combined R&D and SG&A guidance of $830M-$870M (excluding stock comp $700M-$750M). Ended Q1 with approximately $1.1 billion in cash and investments.
CYTK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CYTK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $77.09 | $74.84 | -2.92% |
Feb 24, 2026 | $70.10 | $62.89 | -10.29% |
Nov 05, 2025 | $59.19 | $60.30 | +1.88% |
Aug 07, 2025 | $35.25 | $34.11 | -3.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cytokinetics (CYTK) report earnings?
Cytokinetics (CYTK) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Cytokinetics (CYTK) earnings time?
Cytokinetics (CYTK) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYTK EPS forecast?
CYTK EPS forecast for the fiscal quarter 2026 (Q2) is -1.66.